Van Rompay: Pharmaceutical Dynasty and Diversification with €50M Assets
Van Rompay family
Stijn Van Rompay, a well-known actor in the pharmaceutical industryhas an estimated fortune of 50 million euros, mainly acquired through the founding of Docpharma. His father, Leon, started out in the field with Bayer and Glaxo. He later took the reins of Topgen at Zambon, where he promoted generic drugs. Docpharma was launched with a clear vision: to become a leader in generics. With an impressive IPO on the Brussels stock exchange in 2001, the company's value rose rapidly, culminating in the successful sale of Docpharma in 2005.
| Name | Activities | Contributions |
|---|---|---|
| Stijn Van Rompay | Specialist in anticonceptives at Uteron Pharma, capital contribution of 14 million euros in 2012, founder | Development of natural contraceptives |
| Leon Van Rompay | Interim-CEO of Mithra in 2021 | Stabilization of the company following a scandal |
| Van Rompay family | Investments in hotels and restaurants, including the Ikon nightclub in Antwerp | Expansion in the leisure sector |
Stijn, continuing the family's ambitions, established Hyloriswhich was floated on the Brussels Stock Exchange. Under his leadership, Uteron Pharma worked on an innovative contraceptive based on natural hormones, attracting notable investors. However, despite expectations of an IPO, Uteron was eventually acquired by Activis, an American giant.
Leon Van Rompay played a crucial role as interim CEO of Mithra Pharmaceuticaensuring stability during a tumultuous period marked by a corruption scandal involving François Fornieri. In a less formal context, the family is also involved in investments in horeca and corporate mandates, illustrating the versatility and breadth of their business interests.
The Van Rompay family, known for their spirit entrepreneurialcontinues to exert a significant influence on the pharmaceutical market in Liège while expanding its footprint into other industries and creating a fortune of over €50,000,000.
